CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
22-527

CHEMISTRY REVIEW(S)
ONDQA Division Director’s Memo  
NDA 22-527, Gilenya (fingolimod) Capsules, 0.5 mg  
Date: September 17, 2010

Introduction

Gilenya (fingolimod) Capsules, 0.5 mg are indicated as a disease modifying treatment for relapsing multiple sclerosis. Gilenya (fingolimod) Capsules, 0.5 mg are given once daily, with or without food.

Administrative

This was a rolling NDA submission submitted by Novartis Pharmaceutical Corp. The submission was complete on 21-DEC-2009 (original date of submission of record) and was accepted as a 505(b)(1) priority NDA application. An overall acceptable recommendation was received from The Office of Compliance on 03-FEB-2010. This NDA is supported by IND 70,139. 
ONDQA recommends approval from the CMC perspective.

Drug Substance: Fingolimod hydrochloride

The drug substance is a white to practically white powder. Of the salts studied, the hydrochloride salt exhibited the best solubility characteristics in both water and 0.1 N HCl and the best stability characteristics.

Fingolimod hydrochloride has been used throughout the toxicity and clinical program.

The sponsor manufactures fingolimod hydrochloride in an... The structural elucidation data support the proposed structure of fingolimod hydrochloride.

The purity and quality of the drug substance are maintained through appropriate in-process controls and adequate final drug substance specification. The drug substance specification includes tests and acceptance criteria for description, particle size distribution, color and clarity of solution, identity (IR and XRPD), chromatographic purity (HPLC), residual solvents, heavy metals, assay (HPLC), chloride assay, and microbiological purity. All analytical methods are validated for their intended use. Novartis proposes a retest period for the drug substance.
Drug Product: Fingolimod Capsules 0.5 mg

Fingolimod 0.5 mg hard gelatin capsules are an immediate release dosage form for oral administration. The drug product manufacturing process is straightforward and consists of encapsulation (size 3, hard gelatin capsule), and packaging.

The capsule has a white, opaque body and a bright yellow, opaque cap that contains white to practically white powder. The capsule has a “FTY 0.5 mg” radial imprint with (b)(4) on the cap and two radial bands imprinted on the body with yellow ink. All of the formulation excipients as well as the capsule and ink components comply with compendial or regulatory standards. The drug product does not contain any novel excipients.

Drug product quality is controlled through appropriate in-process controls and final product specifications. These include tests and acceptance criteria for appearance, identification (TLC, HPLC), single-point dissolution, degradation products (HPLC), assay (HPLC), uniformity of dosage forms by content uniformity, and microbial purity. All analytical procedures are appropriately validated for their intended use.

The commercial packaging is blister packs. Novartis proposes a 24 month expiry for the drug product when stored in the commercial packaging at 25°C (77°F); excursions permitted to 15-30°C (59-86°F), protected from moisture.

Rik Lostritto, Ph.D., Director, ONDQA Division I.
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

RICHARD T LOSTRITTO
09/17/2010
NDA 22-527
Quality Review #1
Addendum #2

GILENYA™ (fingolimod) Capsules
0.5 mg

Novartis Pharmaceuticals Corporation

Wendy I. Wilson-Lee, Ph. D.
Office of New Drug Quality Assessment
For
Division of Neurology Drug Products
Table of Contents

Chemistry Review Data Sheet .................................................................................................................3
List of Tables ..............................................................................................................................................6
List of Figures ..............................................................................................................................................6
The Executive Summary ..........................................................................................................................7
I. Recommendations ..........................................................................................................................7
   A. Recommendation and Conclusion on Approvability ..................................................................................7
   B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management
      Steps, if Approvable ....................................................................................................................................7
II. Summary of Chemistry Assessments ....................................................................................................7
   A. Description of the Drug Product(s) and Drug Substance(s) ........................................................................7
   B. Description of How the Drug Product is Intended to be Used ......................................................................8
   C. Basis for Approvability or Not-Approval Recommendation .........................................................................8
III. Administrative .......................................................................................................................................8
   A. Reviewer’s Signature .....................................................................................................................................8
   B. Endorsement Block .....................................................................................................................................8
   C. CC Block ....................................................................................................................................................8

Chemistry Assessment ...........................................................................................................................9

I. Review Of Sponsor’s Responses to IR (emails dated 16-JUL-2010, 09-AUG-2010): ............9
II. Labeling ...................................................................................................................................................11
III. List Of Deficiencies To Be Communicated .............................................................................................12
Chemistry Review Data Sheet

1. NDA: 22-257
2. REVIEW: 01 Addendum 02
3. REVIEW DATE: 26-AUG-2010
4. REVIEWER: Wendy I. Wilson-Lee, Ph.D.

5. PREVIOUS DOCUMENTS:

<table>
<thead>
<tr>
<th>Previous Documents</th>
<th>Document Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Addendum</td>
<td>30-JUN-2010</td>
</tr>
<tr>
<td>Review</td>
<td>30-APR-2010</td>
</tr>
</tbody>
</table>

6. SUBMISSION(S) BEING REVIEWED:

<table>
<thead>
<tr>
<th>Submission(s) Reviewed</th>
<th>Document Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amendment</td>
<td>25-AUG-2010</td>
</tr>
<tr>
<td>Amendment</td>
<td>12-AUG-2010</td>
</tr>
<tr>
<td>Amendment</td>
<td>30-JUL-2010</td>
</tr>
</tbody>
</table>

7. NAME & ADDRESS OF APPLICANT:

Name: Novartis Pharmaceuticals Corporation
Address: One Health Plaza
         East Hanover, NJ 07936-1080
Representative: Mara Stiles,
                RBRM, Drug Regulatory Affairs
Telephone: 862-778-3771

8. DRUG PRODUCT NAME/CODE/TYPE:

a) Proprietary Name: GILENYA™
b) Non-Proprietary Name (USAN): Fingolimod Hydrochloride
c) Code Name/# (ONDQA only): FTY720
d) Chem. Type/Submission Priority (ONDQA only):
   • Chem. Type: 1
   • Submission Priority: P

9. LEGAL BASIS FOR SUBMISSION: 505 (b)(1)
10. PHARMACOL. CATEGORY: Treatment of Relapsing-Remitting Multiple Sclerosis
11. DOSAGE FORM: Capsules
12. STRENGTH/POTENCY: 0.5 mg
13. ROUTE OF ADMINISTRATION: Oral

14. Rx/OTC DISPENSED: _X__Rx ___OTC

15. SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM):
   _____SPOTS product – Form Completed
   _X__Not a SPOTS product

16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:
   Chemical Name: 2-amino-2-[2-(4-octylphenyl)ethyl]propan-1,3-diol hydrochloride
   Mol. Formula: C₁₉H₃₃NO₂•HCl
   Mol. Weight: 343.93 (HCl salt); 307.48 (free base)

17. RELATED/SUPPORTING DOCUMENTS:

   A. DMFs:

<table>
<thead>
<tr>
<th>DMF #</th>
<th>TYPE</th>
<th>HOLDER</th>
<th>ITEM REFERENCED</th>
<th>CODE¹</th>
<th>STATUS²</th>
<th>DATE REVIEW COMPLETED</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>(b) (4)</td>
<td>III</td>
<td>(b) (4)</td>
<td></td>
<td>7</td>
<td>N/A</td>
<td>-</td>
<td>Bottle packaging dropped by sponsor</td>
</tr>
<tr>
<td>(b) (4)</td>
<td>III</td>
<td>(b) (4)</td>
<td></td>
<td>7</td>
<td>N/A</td>
<td>-</td>
<td>Bottle packaging dropped by sponsor</td>
</tr>
<tr>
<td>(b) (4)</td>
<td>III</td>
<td>(b) (4)</td>
<td></td>
<td>7</td>
<td>N/A</td>
<td>-</td>
<td>Bottle packaging dropped by sponsor</td>
</tr>
<tr>
<td>(b) (4)</td>
<td>III</td>
<td>(b) (4)</td>
<td></td>
<td>7</td>
<td>N/A</td>
<td>-</td>
<td>Bottle packaging dropped by sponsor</td>
</tr>
<tr>
<td>(b) (4)</td>
<td>III</td>
<td>(b) (4)</td>
<td></td>
<td>7</td>
<td>N/A</td>
<td>-</td>
<td>Bottle packaging dropped by sponsor</td>
</tr>
<tr>
<td>(b) (4)</td>
<td>III</td>
<td>(b) (4)</td>
<td></td>
<td>7</td>
<td>N/A</td>
<td>-</td>
<td>Bottle packaging dropped by sponsor</td>
</tr>
</tbody>
</table>

¹ Action codes for DMF Table:
1 – DMF Reviewed.
Other codes indicate why the DMF was not reviewed, as follows:
2 – Type 1 DMF
3 – Reviewed previously and no revision since last review
4 – Sufficient information in application
5 – Authority to reference not granted
6 – DMF not available
7 – Other (explain under "Comments")

² Adequate, Inadequate, or N/A (There is enough data in the application, therefore the DMF did not need to be reviewed)
### B. Other Documents:

<table>
<thead>
<tr>
<th>DOCUMENT</th>
<th>APPLICATION NUMBER</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>IND</td>
<td>70,139</td>
<td>FTY720D Capsules for the Treatment of Multiple Sclerosis</td>
</tr>
<tr>
<td>IND</td>
<td>57,293</td>
<td>FTY720A for the Treatment of Prophylaxis of Organ Rejection</td>
</tr>
<tr>
<td>IND</td>
<td>70,407</td>
<td>FTY720 for the Treatment of Hepatitis C</td>
</tr>
</tbody>
</table>

### 18. STATUS:

<table>
<thead>
<tr>
<th>CONSULTS/ CMC RELATED REVIEWS</th>
<th>RECOMMENDATION</th>
<th>DATE</th>
<th>REVIEWER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biometrics</td>
<td>Acceptable</td>
<td>01-JUL-2010</td>
<td>X. Yan</td>
</tr>
<tr>
<td>EES</td>
<td>Acceptable.</td>
<td>03-FEB-2010</td>
<td>M. Stock</td>
</tr>
<tr>
<td>Pharm/Tox</td>
<td>Pending.</td>
<td>-</td>
<td>R. Siarey</td>
</tr>
<tr>
<td>Biopharm</td>
<td>Acceptable.</td>
<td>04-AUG-2010</td>
<td>J. Lai</td>
</tr>
<tr>
<td>LNC</td>
<td>N/A</td>
<td>04-AUG-2010</td>
<td>J. Lai</td>
</tr>
<tr>
<td>Methods Validation</td>
<td>Method validation by FDA laboratory not needed.</td>
<td>20-JAN-2010</td>
<td>W. Wilson-Lee</td>
</tr>
<tr>
<td>DMEPA</td>
<td>GILENYA™ tradename granted.</td>
<td>23-AUG-2010</td>
<td>D. Baugh</td>
</tr>
<tr>
<td></td>
<td>Labeling acceptable, with edits.</td>
<td>25-MAY-2010</td>
<td>F. Duffy</td>
</tr>
<tr>
<td>EA</td>
<td>Categorical exclusion granted.</td>
<td>31-AUG-2009</td>
<td>W. Wilson-Lee</td>
</tr>
<tr>
<td>Microbiology</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>
List of Tables

Table 1 - Final GILENYA™ Regulatory Specification ...............................................................................................................................................10

List of Figures

Figure 1 - GILENYA™ Carton and Container Labels ..................................................................................................................................................11
Chemistry Review for NDA 22-527

The Executive Summary

I. Recommendations

A. Recommendation and Conclusion on Approvability

From a CMC perspective, we recommend approval of 0.5 mg GILENYA™ (fingolimod) Capsules, pending labeling.

B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable

We have no CMC Phase 4 commitments at this time.

II. Summary of Chemistry Assessments

A. Description of the Drug Product(s) and Drug Substance(s)

Fingolimod hydrochloride, a novel synthetic sphingosine analogue, is an S1P-receptor modulator that reversibly traps a proportion of lymphocytes in the lymph nodes, thereby reducing their recirculation in the bloodstream and the central nervous system. The drug substance is a white to practically white powder. During development of the drug substance, the base and salts of fingolimod were manufactured and tested for stability, solubility and polymorphic properties. Based on this testing, the hydrochloride salt was chosen for further development. It exhibited the best solubility characteristics in both water and 0.1 N HCl and the best stability characteristics with a standard excipient mixture.

The structural elucidation data support the proposed structure of fingolimod hydrochloride. The identity and quality of the drug substance is assured through appropriate in-process controls and adequate final drug substance specification. The drug substance specification includes tests and acceptance criteria for description, particle size distribution, color and clarity of solution, identity (IR and XRPD), chromatographic purity (HPLC), residual solvents, heavy metals, \(^{(b)}\) assay (HPLC), chloride assay, and microbiological purity. All analytical methods are validated for their intended use. Novartis proposes a \(^{(b)}\) retest period for the drug substance.
Fingolimod 0.5 mg hard gelatin capsules are an immediate release dosage form for oral administration. The 0.5 mg strength drug product is a size 3 capsule with a white, opaque body and a bright yellow, opaque cap that contains white to practically white powder. The capsule has a “FTY 0.5 mg” radial imprint on the cap and two radial bands imprinted on the body with yellow ink. All of the formulation excipients as well as the capsule and ink components comply with compendial or regulatory standards. The drug product does not contain any novel excipients.

The manufacturing process is straightforward and consists of encapsulation, and packaging. The drug product quality is controlled through appropriate in-process controls and final product specification. The drug product specification includes tests and acceptance criteria for appearance, identification (TLC, HPLC), single-point dissolution, degradation products (HPLC), assay (HPLC), uniformity of dosage forms by content uniformity, and microbial purity. All analytical procedures are appropriately validated for their intended use. The commercial packaging is blister packs. Novartis proposes a 24 month expiry for this product when stored in the commercial packaging at 25°C (77°F); excursions permitted to 15-30°C (59-86°F), protected from moisture.

**B. Description of How the Drug Product is Intended to be Used**

Fingolimod capsules are indicated as a disease modifying therapy for the treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations and to delay physical disability. The recommended daily dose is 0.5 mg fingolimod. Fingolimod 0.5 mg capsules are for oral administration once daily, with or without food. Fingolimod capsules are supplied in blister packs as a carton of 28 capsules or as a physician sample (one blister strip of 7 capsules in a carton).

**C. Basis for Approvability or Not-Approval Recommendation**

From a CMC perspective, we recommend approval of 0.5 mg GILENYA® (fingolimod) capsules, pending labeling. The sponsor adequately responded to our request to revise the drug product regulatory specification to limit the shelf-life limit of the to NMT. The updated carton and container labels are adequate.

**III. Administrative**

**A. Reviewer’s Signature**

_Wendy I. Wilson-Lee_

**B. Endorsement Block**

<table>
<thead>
<tr>
<th>Wilson-Lee</th>
<th>26-AUG-2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>MHeimann</td>
<td>26-AUG-2010</td>
</tr>
<tr>
<td>RSood</td>
<td>26-AUG-2010</td>
</tr>
</tbody>
</table>

**C. CC Block**

<table>
<thead>
<tr>
<th>TBoie</th>
</tr>
</thead>
<tbody>
<tr>
<td>DHenry</td>
</tr>
<tr>
<td>HToumet</td>
</tr>
</tbody>
</table>

4 page(s) have been Withheld in Full immediately following this page as B4 (CCI/TS)
<table>
<thead>
<tr>
<th>Application Type/Number</th>
<th>Submission Type/Number</th>
<th>Submitter Name</th>
<th>Product Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA-22527</td>
<td>ORIG-1</td>
<td>NOVARTIS PHARMACEUTICALS CORP</td>
<td>FINGOLIMOD HCL ORAL CAPSULES</td>
</tr>
</tbody>
</table>

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

WENDY I WILSON
09/01/2010

RAMESH K SOOD
09/01/2010
Summary and Critical Issues:

Summary

Fingolimod hydrochloride (FTY720) is a new molecular entity developed by Novartis. It is a novel sphingosine analogue that acts as a sphingosine 1-phosphate (S1P)-receptor modulator that reversibly traps a proportion of lymphocytes in the lymph nodes, thereby reducing their recirculation in the bloodstream and the central nervous system. FTY720 was initially studied (in combination with cyclosporine) as prophylaxis for organ rejection in renal transplantation but failed to show any benefit in Phase 3 trials. Novartis subsequently developed FTY720 for treatment of relapsing-remitting multiple sclerosis (RRMS). The firm was granted fast-track status for the RRMS indication and seeks to market FTY720 The initial submission to the rolling NDA consists of the CMC and nonclinical sections of the application.

Drug Substance

The active ingredient, fingolimod hydrochloride, is a small molecule with molecular formula C_{19}H_{33}NO_{2}•HCl. The molecular weight of the salt form and free base are 343.93 and 307.48, respectively. The chemical name is 2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propandiol, hydrochloride. There are no chiral centers. The structural formula of fingolimod hydrochloride is:
The drug substance is a white to practically white powder. It is soluble (>10%) in water, 0.9% saline and aqueous buffers at or below pH 2.0. It is very slightly soluble or practically insoluble in aqueous buffers at or above pH 3.0. The applicant states that fingolimod hydrochloride shows at

Fingolimod hydrochloride is manufactured by Novartis at the firm's facilities in Switzerland. The manufacturing process is outlined in Figures 2-1 and 2-2. The bulk drug substance is manufactured in

Figure 2-1   Synthesis scheme Fingolimod Hydrochloride (FTY720)
The proposed drug substance specification is reproduced below (Table 4-1). The proposed analytical procedures for fingolimod hydrochloride are straight-forward. Assay and related substances are determined using a HPLC method. Analytical procedures and method validation data are included in the NDA.

<table>
<thead>
<tr>
<th>Table 4-1</th>
<th>Fingolimod HCl specifications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Test</td>
<td>Requirement</td>
</tr>
<tr>
<td>Description</td>
<td>Appearance (visual examination)</td>
</tr>
<tr>
<td></td>
<td>Particle size</td>
</tr>
<tr>
<td>Physico-chemical properties</td>
<td>(b)(4)</td>
</tr>
</tbody>
</table>
The applicant has submitted long-term stability data through 60 months, plus 12 months intermediate stability data and 6 months accelerated data on three pilot scale drug substance batches. A retest date of [redacted] is proposed. A standard stability commitment for full-scale post approval batches is provided.

**Drug Product**

The proposed dosage form is an immediate release capsule containing 0.5 mg [redacted] fingolimod as the hydrochloride salt. The 0.5 mg presentation is a size 3 capsule with white opaque body and bright yellow opaque cap, radial imprint with [redacted], “FTY 0.5 mg” on cap and two radial bands imprinted on the body with yellow ink.

The capsule fill formulation is the same as that used in...
clinical studies under the RRMS IND. The only differences between the clinical and commercial images are capsule shell color and imprinting.

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Amount per 0.5 mg capsule (mg)</th>
<th>Reference to standards</th>
<th>Function</th>
</tr>
</thead>
<tbody>
<tr>
<td>FTY720 HCl</td>
<td>0.56</td>
<td>Novartis monograph</td>
<td>Drug substance</td>
</tr>
<tr>
<td>Mannitol</td>
<td>(b)(4)</td>
<td>USP, Ph. Eur.</td>
<td></td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>(b)(4)</td>
<td>NF, Ph. Eur.</td>
<td></td>
</tr>
</tbody>
</table>

**Table 1-1: Composition of FTY720 hard capsules**

Empty capsule shell, pre-printed
- Capsule shell (theoretical weight) 3
- Printing ink, yellow 4

Total capsule weight

1 2-Amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride. The molecular weight ratio of FTY720 HCl to FTY720 base is approximately 1.12 to 1.0
2 The composition of the capsule shells are provided in Table 1-2 and Table 1-3
3 The qualitative composition of the inks is provided in Table 1-4.

The inactive ingredients, mannitol and magnesium stearate, comply with compendial requirements. The choice of capsule presentation and excipients is based on the functionality of the active ingredient, which is incompatible with most common diluents other than mannitol. Formulations containing mannitol exhibited

The commercial product will be manufactured by Novartis at the firm's Stein, Switzerland facility. The manufacturing process involves  and encapsulation processes. Limited information regarding process development is provided in the Pharmaceutical Development section.

Acceptance criteria for the 0.5 mg strength are the same.
Assay and related substances are determined using HPLC method. A similar method is used for determination of content uniformity. Dissolution results are quantitated using a separate method.

The applicant proposes marketing of Fingolimod Capsules in blister packs. The blister packs use film backed with aluminum foil.

The NDA stability package includes long-term stability data through 18 months, intermediate data through 12 months, and accelerated data through 6 months for three production-scale batches per strength. All batches were manufactured at the Stein Switzerland facility and packaged in the proposed commercial packaging presentations. It is noted that some batches failed assay/related substances testing at the accelerated stability condition but all batches remained within specification through 12 months at the intermediate storage condition. A 24-month shelf life is proposed based on statistical analysis of the long-term assay results.

**Critical issues for review**

**Drug Substance**

The drug substance is manufactured using well preceded synthetic methodology. No critical issues related to manufacture and control of the drug substance were identified during the initial assessment.

**Drug Product**

The drug product is an immediate release capsule manufactured using and encapsulation processes. Two critical issues were identified during the initial assessment. The first is blend uniformity/content uniformity within the capsules. The second issue is the reactivity of the active ingredient. The applicant has tried to minimize degradation through however, some degradation is still observed under long-term storage conditions. The reviewer should consult with the pharmacology review team to verify that all degradation products have been adequately qualified in nonclinical toxicology studies.

**Additional issues**

**Administrative:** A claim for categorical exclusion is included in Module 1 of the application.

**Establishment Evaluation:** PENDING

**Labeling/Established Name:** The USAN name for the drug substance is fingolimod hydrochloride. The potency claim, however, is based on content of the free base. Labeling is
not provided in the current submission. When labeling is submitted, the reviewer should verify that the correct established name, i.e., "fingolimod capsules" is used in product labeling.

Comments for 74-Day Letter

There are no comments for the 74 day letter

Review, Comments and Recommendation:

The CMC portion of the NDA is complete and reviewable. A recommendation regarding fileability is deferred pending submission of the complete application. The drug substance is a new molecular entity. The dosage form, however, is a very simple formulation containing only two excipients, mannitol and magnesium stearate and there are no QbD aspects to the application. Assignment of the NDA to a single reviewer is recommended.

Martha R. Heimann, Ph.D.
Pharmaceutical Assessment Lead, DPA 1, ONDQA Date

Ramesh Sood, Ph.D.
Branch Chief, DPA 1, ONDQA Date
The following parameters are necessary in order to initiate a full review, i.e., complete enough to review but may have deficiencies.

<table>
<thead>
<tr>
<th>Content Parameter</th>
<th>Yes</th>
<th>No</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Is the section legible, organized, indexed, and paginated adequately?</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Are ALL of the manufacturing and testing sites (including contract sites)</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(including contract sites) identified with full street addresses (and CFNs, if</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>applicable)?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Is a statement provided to indicate whether each manufacturing or testing site</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>is ready for inspection or, if not, when it will be ready?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Is a statement on the Environmental Impact provided as required in 21 CFR</td>
<td>X</td>
<td></td>
<td>A claim for categorical exclusion was</td>
</tr>
<tr>
<td>314.50(d)(1)(iii)?</td>
<td></td>
<td></td>
<td>submitted.</td>
</tr>
<tr>
<td>5. Is information on the Drug Substance provided as required in 21 CFR 314.50(d)</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(1)(i)?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Is information on the Drug Product provided as required in 21 CFR 314.50(d)</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(1)(ii)?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. If applicable, has all information requested during the IND phases, and at the</td>
<td>NA</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>pre-NDA meetings been included?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8. Have draft container labels and package insert been provided?</td>
<td>X</td>
<td></td>
<td>Labeling is not part of the CMC reviewable</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>unit.</td>
</tr>
<tr>
<td>9. Have all DMF References been identified?</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10. Is information on the investigational formulations included?</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11. Is information on the Methods Validation included?</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12. If applicable, is documentation on the sterilization process validation</td>
<td>NA</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>included?</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**IS THE CMC SECTION OF THE APPLICATION FILEABLE?**

If the NDA is not fileable from chemistry, manufacturing, and controls perspective, state the reasons and provide comments to be sent to the Applicant. **NA**

Martha R. Heimann, Ph.D.
Pharmaceutical Assessment Lead, DPA 1, ONDQA
Date

Ramesh Sood, Ph.D.
Branch Chief, DPA 1, ONDQA
Date
# Manufacturing Facilities for Fingolimod Capsules

## Drug Substance

<table>
<thead>
<tr>
<th>Establishment</th>
<th>Contact Information</th>
<th>Establishment Registration #</th>
<th>Responsibility</th>
</tr>
</thead>
<tbody>
<tr>
<td>Novartis Pharma AG Lichtstrasse 35 CH-4056 Basel Switzerland</td>
<td>Michael Bruckheimer Director Global Compliance and Auditing Tel.: (862) 778-7913 <a href="mailto:michael.bruckheimer@novartis.com">michael.bruckheimer@novartis.com</a></td>
<td>9611204</td>
<td>Manufacture of intermediate quality control</td>
</tr>
<tr>
<td>Novartis Pharma Schweizerhalle AG Rothausweg CH-4133 Pratteln Switzerland</td>
<td>Michael Bruckheimer Director Global Compliance and Auditing Tel.: (862) 778-7913 <a href="mailto:michael.bruckheimer@novartis.com">michael.bruckheimer@novartis.com</a></td>
<td>9692042</td>
<td>Manufacture of Fingolimod Hydrochloride quality control</td>
</tr>
<tr>
<td>Novartis Pharma Stein AG Schaffhauserstrasse CH-4332 Stein Switzerland</td>
<td>Michael Bruckheimer Director Global Compliance and Auditing Tel.: (862) 778-7913 <a href="mailto:michael.bruckheimer@novartis.com">michael.bruckheimer@novartis.com</a></td>
<td>9692043</td>
<td>(b) (4)</td>
</tr>
<tr>
<td>Novartis International Pharmaceutical Ltd. Branch Ireland Ringaskiddy Co. Cork Ireland</td>
<td>Michael Bruckheimer Director Global Compliance and Auditing Tel.: (862) 778-7913 <a href="mailto:michael.bruckheimer@novartis.com">michael.bruckheimer@novartis.com</a></td>
<td>9612715</td>
<td>Quality control, stability testing</td>
</tr>
</tbody>
</table>

## Drug Product

<table>
<thead>
<tr>
<th>Establishment</th>
<th>Contact Information</th>
<th>Establishment Registration No.</th>
<th>Responsibility</th>
</tr>
</thead>
<tbody>
<tr>
<td>Novartis Pharma Stein AG Schaffhauserstrasse CH-4332 Stein Switzerland</td>
<td>Michael Bruckheimer Director Global Compliance and Auditing Tel.: (862) 778-7913 <a href="mailto:michael.bruckheimer@novartis.com">michael.bruckheimer@novartis.com</a></td>
<td>9692043</td>
<td>Manufacture, quality control, packaging</td>
</tr>
<tr>
<td>Novartis Pharmaceuticals Corporation (Suffern) 25 Old Mill Road Suffern, New York 10901 USA</td>
<td>Ernesto Alfonso Executive Director, QA Tel.: (862) 368-6462 <a href="mailto:Ernesto.alfonso@novartis.com">Ernesto.alfonso@novartis.com</a></td>
<td>2416082</td>
<td>Quality control, stability testing, packaging</td>
</tr>
</tbody>
</table>
# Manufacturing Facilities for Fingolimod Capsules

## Drug Product

<table>
<thead>
<tr>
<th>Establishment</th>
<th>Contact Information</th>
<th>Establishment Registration No.</th>
<th>Responsibility</th>
</tr>
</thead>
</table>
| Novartis Pharmanalytica S.A.  
Via Serafino Balestra 31  
CH-6601 Locarno  
Switzerland                   | Michael Bruckheimer  
Director Global Compliance and Auditing  
Tel.: (862) 778-7913  
michael.bruckheimer@novartis.com | 9614433                        | Stability testing      |
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
---------------------
Martha Heimann
6/29/2009 02:44:00 PM
CHEMIST

Ramesh Sood
6/29/2009 03:48:39 PM
CHEMIST
NDA 22-527
Quality Review #1
Addendum #1

Fingolimod Capsules
0.5 mg

Novartis Pharmaceuticals Corporation

Wendy I. Wilson-Lee, Ph. D.
Office of New Drug Quality Assessment
For
Division of Neurology Drug Products
**Table of Contents**

**Table of Contents** .................................................................................................................................................2

**Chemistry Review Data Sheet** ...............................................................................................................................3

**List of Tables** ..........................................................................................................................................................6

**List of Figures** ........................................................................................................................................................6

**The Executive Summary** ...........................................................................................................................................7

I. Recommendations ............................................................................................................................................................7
   A. Recommendation and Conclusion on Approvability.................................................................................................7
   B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management
      Steps, if Approvable ........................................................................................................................................7

II. Summary of Chemistry Assessments .........................................................................................................................7
   A. Description of the Drug Product(s) and Drug Substance(s).....................................................................................7
   B. Description of How the Drug Product is Intended to be Used ....................................................................................8
   C. Basis for Approvability or Not-Approval Recommendation.....................................................................................8

III. Administrative ..............................................................................................................................................................8
   A. Reviewer’s Signature ....................................................................................................................................................8
   B. Endorsement Block ....................................................................................................................................................8
   C. CC Block .................................................................................................................................................................8

**Chemistry Assessment** ...............................................................................................................................................9

I. Review Of Sponsor’s Responses to CMC IR#2 (letter dated 07-MAY-2010): .................................................9

II. Other Issues ...................................................................................................................................................................18

III. List Of Deficiencies To Be Communicated ............................................................................................................18
Chemistry Review Data Sheet

1. NDA: 22-257
2. REVIEW: 01 Addendum 01
3. REVIEW DATE: 22-JUN-2010
4. REVIEWER: Wendy I. Wilson-Lee, Ph.D.

5. PREVIOUS DOCUMENTS:

<table>
<thead>
<tr>
<th>Previous Documents</th>
<th>Document Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Review</td>
<td>30-APR-2010</td>
</tr>
</tbody>
</table>

6. SUBMISSION(S) BEING REVIEWED:

<table>
<thead>
<tr>
<th>Submission(s) Reviewed</th>
<th>Document Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amendment</td>
<td>16-JUN-2010</td>
</tr>
<tr>
<td>Amendment</td>
<td>24-MAY-2010</td>
</tr>
</tbody>
</table>

7. NAME & ADDRESS OF APPLICANT:

<table>
<thead>
<tr>
<th>Name:</th>
<th>Novartis Pharmaceuticals Corporation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Address:</td>
<td>One Health Plaza East Hanover, NJ 07936-1080</td>
</tr>
<tr>
<td>Representative:</td>
<td>Mara Stiles, RBRM, Drug Regulatory Affairs</td>
</tr>
<tr>
<td>Telephone:</td>
<td>862-778-3771</td>
</tr>
</tbody>
</table>

8. DRUG PRODUCT NAME/CODE/TYPE:

a) Proprietary Name: Gilenya™ (proposed) [alternate – Gylenia™]
b) Non-Proprietary Name (USAN): Fingolimod Hydrochloride
c) Code Name/# (ONDQA only): FTY720
d) Chem. Type/Submission Priority (ONDQA only):
   - Chem. Type: 1
   - Submission Priority: P

9. LEGAL BASIS FOR SUBMISSION: 505 (b)(1)

10. PHARMACOL. CATEGORY: Treatment of Relapsing-Remitting Multiple Sclerosis

11. DOSAGE FORM: Capsules

12. STRENGTH/POTENCY: 0.5 mg

13. ROUTE OF ADMINISTRATION: Oral
14. Rx/OTC DISPENSED: _X__Rx   ___OTC

15. SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM):
   SPOTS product – Form Completed
   X   Not a SPOTS product

16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:
   Chemical Name: 2-amino-2-[2-(4-octylphenyl)ethyl]propan-1,3-diol hydrochloride
   Mol. Formula: C₁₉H₃₃NO₂•HCl
   Mol. Weight: 343.93 (HCl salt); 307.48 (free base)

17. RELATED/SUPPORTING DOCUMENTS:

A. DMFs:

<table>
<thead>
<tr>
<th>DMF #</th>
<th>TYPE</th>
<th>HOLDER</th>
<th>ITEM REFERENCED</th>
<th>CODE¹</th>
<th>STATUS²</th>
<th>DATE REVIEW COMPLETED</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>7</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>7</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>7</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1</td>
<td>Adequate</td>
<td>23-FEB-2010</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1</td>
<td>Adequate</td>
<td>19-FEB-2010</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>7</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

¹ Action codes for DMF Table:
1 – DMF Reviewed.
Other codes indicate why the DMF was not reviewed, as follows:
2 – Type 1 DMF
3 – Reviewed previously and no revision since last review
4 – Sufficient information in application
5 – Authority to reference not granted
6 – DMF not available
7 – Other (explain under "Comments")

² Adequate, Inadequate, or N/A (There is enough data in the application, therefore the DMF did not need to be reviewed)

B. Other Documents:
### CHEMISTRY REVIEW

#### DOCUMENT APPLICATION NUMBER DESCRIPTION

<table>
<thead>
<tr>
<th>DOCUMENT</th>
<th>APPLICATION NUMBER</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>IND</td>
<td>70,139</td>
<td>FTY720D Capsules for the Treatment of Multiple Sclerosis</td>
</tr>
<tr>
<td>IND</td>
<td>57,293</td>
<td>FTY720A for the Treatment of Prophylaxis of Organ Rejection</td>
</tr>
<tr>
<td>IND</td>
<td>70,407</td>
<td>FTY720 for the Treatment of Hepatitis C</td>
</tr>
</tbody>
</table>

#### 18. STATUS:

<table>
<thead>
<tr>
<th>CONSULTS/CMC RELATED REVIEWS</th>
<th>RECOMMENDATION</th>
<th>DATE</th>
<th>REVIEWER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biometrics</td>
<td>Pending.</td>
<td>-</td>
<td>X. Yan</td>
</tr>
<tr>
<td>EES</td>
<td>Acceptable.</td>
<td>03-FEB-2010</td>
<td>M. Stock</td>
</tr>
<tr>
<td>Pharm/Tox</td>
<td>Pending.</td>
<td>-</td>
<td>R. Siarey</td>
</tr>
<tr>
<td>Biopharm</td>
<td>Pending.</td>
<td>-</td>
<td>J. Lai</td>
</tr>
<tr>
<td>LNC</td>
<td>N/A</td>
<td></td>
<td>-</td>
</tr>
<tr>
<td>Methods Validation</td>
<td>Method validation by FDA laboratory not needed.</td>
<td>20-JAN-2010</td>
<td>W. Wilson-Lee</td>
</tr>
<tr>
<td>DMEPA</td>
<td>Objection to proposed tradename, Gilenia®.</td>
<td>05-MAY-2010</td>
<td>F. Duffy</td>
</tr>
<tr>
<td>EA</td>
<td>Categorical exclusion granted.</td>
<td>31-AUG-2009</td>
<td>W. Wilson-Lee</td>
</tr>
<tr>
<td>Microbiology</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>
List of Tables

Table 1-1: Blending and Parameters of Fingolimod Hydrochloride.................................................................9
Table 2-1: Proposed Specification Changes for ..................................................................................................10
Table 2-2: Residual Starting Materials Found in ..............................................................................................10
Table 2-3: Residual Starting Materials Found in ..............................................................................................10
Table 3-1: Revised Fingolimod Hydrochloride Regulatory Specification..........................................................11
Table 4-1: Comparison of Bulk and Tapped Density Results of Mannitol from Three Vendors..................................................12
Table 4-2: Comparison of BET Surface Area for Mannitol from Three Vendors....................................................12
Table 5-2: Effect of Increased Magnesium Stearate Content on Fingolimod Drug Release......................................14
Table 8-1: Mannitol Regulatory Particle Size Distribution Specification............................................................15
Table 9-1: Revised Gilenya™ Drug Product Regulatory Specification...............................................................16
Table 10-1: Comparison of Fingolimod Drug Release from Manual vs. Automated Sampling............................17

List of Figures

Figure 4-4: Comparison of Moisture Adsorption/Desorption Isotherms for Mannitol from Three Vendors..................12
Figure 4-5: Comparison of Normalized Surface Area for Mannitol from Three Vendors..............................................13
Figure 4-6: SEM of Mannitol from Three Vendors..............................................................................................13
Figure 4-7: PSD Results for Mannitol from Three Vendors....................................................................................13
Figure 4-8: PSD Results for Mannitol..................................................................................................................13
Figure 5-1: Effect of Increased Magnesium Stearate Content on Fingolimod Drug Release......................................14
Figure 10-1: Comparison of Fingolimod Drug Release for Manual vs. Automated Sampling..............................17
The Executive Summary

I. Recommendations

A. Recommendation and Conclusion on Approvability

From a CMC perspective, we cannot recommend approval for fingolimod capsules 0.5 mg. During the review cycle, we identified the proposed shelf-life limit (NMT (b)(4)) for the drug product degradant (b)(4) as exceeding the ICH qualification threshold (NMT 1.0%). We informed the pharm/tox review of this issue and asked for a final recommendation as to whether or not the (b)(4) is qualified at (b)(4) based on nonclinical studies. To date, the pharm/tox review team has not provided a final recommendation concerning this issue and therefore, CMC cannot offer a final recommendation concerning approval of this NDA. If the pharm/tox review team recommends approval of the proposed shelf-life limit, no further action from CMC will be needed. However, if the pharm/tox review team does not consider the qualified at the proposed shelf-life limit, the sponsor will need to revise the drug product regulatory specification and submit the revised specification for review prior to our final CMC recommendation.

B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable

We have no CMC Phase 4 commitments at this time.

II. Summary of Chemistry Assessments

A. Description of the Drug Product(s) and Drug Substance(s)

Fingolimod hydrochloride, a novel synthetic sphingosine analogue, is an S1P-receptor modulator that reversibly traps a proportion of lymphocytes in the lymph nodes, thereby reducing their recirculation in the bloodstream and the central nervous system. The drug substance is a white to practically white powder. During development of the drug substance, the base and salts of fingolimod were manufactured and tested for stability, solubility and polymorphic properties. Based on this testing, the hydrochloride salt was chosen for further development. It exhibited the best solubility characteristics in both water and 0.1 N HCl and the best stability characteristics with a standard excipient mixture.

Fingolimod hydrochloride (b)(4) is the desired form used throughout the toxicity and clinical program.

The sponsor manufactures fingolimod in (b)(4)
The structural elucidation data support the proposed structure of fingolimod hydrochloride. The identity and quality of the drug substance is assured through appropriate in-process controls and adequate final drug substance specification. The drug substance specification includes tests and acceptance criteria for description, particle size distribution, color and clarity of solution, identity (IR and XRPD), chromatographic purity (HPLC), residual solvents, heavy metals, assay (HPLC), chloride assay, and microbiological purity. All analytical methods are validated for their intended use. Novartis proposes a retest period for the drug substance.

Fingolimod 0.5 mg hard gelatin capsules are an immediate release dosage form for oral administration. The 0.5 mg strength drug product is a size 3 capsule with a white, opaque body and a bright yellow, opaque cap that contains white to practically white powder. The capsule has a “FTY 0.5 mg” radial imprint on the cap and two radial bands imprinted on the body with yellow ink. All of the formulation excipients as well as the capsule and ink components comply with compendial or regulatory standards. The drug product does not contain any novel excipients.

The manufacturing process is straightforward and consists of encapsulation, and packaging. The drug product quality is controlled through appropriate in-process controls and final product specification. The drug product specification includes tests and acceptance criteria for appearance, identification (TLC, HPLC), single-point dissolution, degradation products (HPLC), assay (HPLC), uniformity of dosage forms by content uniformity, and microbial purity. All analytical procedures are appropriately validated for their intended use. The commercial packaging is blister packs. Novartis proposes a 24 month expiry for this product when stored in the commercial packaging at 25°C (77°F); excursions permitted to 15-30°C (59-86°F), protected from moisture.

B. Description of How the Drug Product is Intended to be Used

Fingolimod capsules are indicated as a disease modifying therapy for the treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations and to delay physical disability. The recommended daily dose 0.5 mg fingolimod. Fingolimod 0.5 mg capsules are for oral administration once daily, with or without food. Fingolimod capsules are supplied in blister packs as a carton of 28 capsules or as a physician sample (one blister strip of 7 capsules in a carton).

C. Basis for Approvability or Not-Approval Recommendation

From a CMC perspective, we cannot recommend approval of fingolimod capsules 0.5 mg, pending a recommendation from pharm/tox regarding the proposed shelf-life limit for the drug product degradant. The sponsor adequately responded to our requests and provided information demonstrating that the manufacturing processes consistently produce drug substance and drug product of adequate quality.
<table>
<thead>
<tr>
<th>Application Type/Number</th>
<th>Submission Type/Number</th>
<th>Submitter Name</th>
<th>Product Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA-22527</td>
<td>ORIG-1</td>
<td>NOVARTIS PHARMACEUTICALS CORP</td>
<td>FINGOLIMOD HCL ORAL CAPSULES</td>
</tr>
</tbody>
</table>

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

WENDY I WILSON  
06/30/2010

RAMESH K SOOD  
06/30/2010
NDA 22-527
Quality Review #1

Fingolimod Capsules
0.5 mg

Novartis Pharmaceuticals Corporation

Wendy I. Wilson-Lee, Ph. D.
Office of New Drug Quality Assessment
For
Division of Neurology Drug Products
Table of Contents

Table of Contents .........................................................................................................................2

Chemistry Review Data Sheet ........................................................................................................3

List of Tables ....................................................................................................................................6

List of Figures ...................................................................................................................................8

The Executive Summary .................................................................................................................9

I. Recommendations ......................................................................................................................9
   A. Recommendation and Conclusion on Approvability ...............................................................9
   B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable ...............................................................9

II. Summary of Chemistry Assessments .......................................................................................9
   A. Description of the Drug Product(s) and Drug Substance(s) ..................................................9
   B. Description of How the Drug Product is Intended to be Used .............................................10
   C. Basis for Approvability or Not-Approval Recommendation ..............................................10

III. Administrative ........................................................................................................................10
   A. Reviewer’s Signature ..............................................................................................................10
   B. Endorsement Block ..............................................................................................................10
   C. CC Block ...............................................................................................................................10

Chemistry Assessment ..............................................................................................................11

   S DRUG SUBSTANCE [Fingolimod Hydrochloride, Novartis Pharmaceuticals Corp.] ...........11
   P DRUG PRODUCT [Gilenia® (proposed), Capsule] ................................................................53
   A APPENDICES .......................................................................................................................89
   R REGIONAL INFORMATION .................................................................................................89

II. Review Of Common Technical Document-Quality (Ctd-Q) Module 1 ..................................90
   A. Labeling & Package Insert ..................................................................................................90
   B. Environmental Assessment Or Claim Of Categorical Exclusion ........................................94
   C. Establishment Inspection ....................................................................................................95

III. List Of Deficiencies To Be Communicated .............................................................................99

IV. Other Issues ...........................................................................................................................100
Chemistry Review Data Sheet

1. NDA: 22-257
2. REVIEW: 01
3. REVIEW DATE: 30-APR-2010
4. REVIEWER: Wendy I. Wilson, Ph.D.
5. PREVIOUS DOCUMENTS:

<table>
<thead>
<tr>
<th>Previous Documents</th>
<th>Document Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>None.</td>
<td>N/A</td>
</tr>
</tbody>
</table>

6. SUBMISSION(S) BEING REVIEWED:

<table>
<thead>
<tr>
<th>Submission(s) Reviewed</th>
<th>Document Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amendment</td>
<td>16-MAR-2010</td>
</tr>
<tr>
<td>Amendment</td>
<td>11-MAR-2010</td>
</tr>
<tr>
<td>Amendment</td>
<td>21-DEC-2009</td>
</tr>
<tr>
<td>Amendment</td>
<td>24-JUL-2009</td>
</tr>
<tr>
<td>Original</td>
<td>16-JUN-2009</td>
</tr>
</tbody>
</table>

7. NAME & ADDRESS OF APPLICANT:

<table>
<thead>
<tr>
<th>Name:</th>
<th>Novartis Pharmaceuticals Corporation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Address:</td>
<td>One Health Plaza</td>
</tr>
<tr>
<td></td>
<td>East Hanover, NJ 07936-1080</td>
</tr>
<tr>
<td>Representative:</td>
<td>Mara Stiles, RBRM, Drug Regulatory Affairs</td>
</tr>
<tr>
<td>Telephone:</td>
<td>862-778-3771</td>
</tr>
</tbody>
</table>

8. DRUG PRODUCT NAME/CODE/TYPE:

a) Proprietary Name: Gilenia® (proposed)
b) Non-Proprietary Name (USAN): Fingolimod Hydrochloride
c) Code Name/# (ONDQA only): FTY720
d) Chem. Type/Submission Priority (ONDQA only):
   - Chem. Type: 1
   - Submission Priority: P

9. LEGAL BASIS FOR SUBMISSION: 505(b)(1)

10. PHARMACOL. CATEGORY: Treatment of Relapsing-Remitting Multiple Sclerosis

11. DOSAGE FORM: Capsules

12. STRENGTH/POTENCY: 0.5 mg
13. ROUTE OF ADMINISTRATION: Oral

14. Rx/OTC DISPENSED: \_X\_Rx \_\_\_OTC

15. SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM):
   - _____SPOTS product – Form Completed
   - \_X\_ Not a SPOTS product

16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:
   Chemical Name: 2-amino-2-[2-(4-octylphenyl)ethyl]propan-1,3-diol hydrochloride
   Mol. Formula: $C_{19}H_{33}NO_2\cdot HCl$
   Mol. Weight: 343.93 (HCl salt); 307.48 (free base)

17. RELATED/SUPPORTING DOCUMENTS:
   **A. DMFs:**

<table>
<thead>
<tr>
<th>DMF #</th>
<th>TYPE</th>
<th>HOLDER</th>
<th>ITEM REFERENCED</th>
<th>CODE</th>
<th>STATUS</th>
<th>DATE REVIEW COMPLETED</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>(b) (4)</td>
<td>III</td>
<td>(b) (4)</td>
<td></td>
<td>7</td>
<td>N/A</td>
<td>-</td>
<td>Bottle packaging dropped by sponsor</td>
</tr>
<tr>
<td>(b) (4)</td>
<td>III</td>
<td>(b) (4)</td>
<td></td>
<td>7</td>
<td>N/A</td>
<td>-</td>
<td>Bottle packaging dropped by sponsor</td>
</tr>
<tr>
<td>(b) (4)</td>
<td>III</td>
<td>(b) (4)</td>
<td></td>
<td>7</td>
<td>N/A</td>
<td>-</td>
<td>Bottle packaging dropped by sponsor</td>
</tr>
<tr>
<td>(b) (4)</td>
<td>III</td>
<td>(b) (4)</td>
<td></td>
<td>7</td>
<td>N/A</td>
<td>-</td>
<td>Bottle packaging dropped by sponsor</td>
</tr>
<tr>
<td>(b) (4)</td>
<td>III</td>
<td>(b) (4)</td>
<td></td>
<td>7</td>
<td>N/A</td>
<td>-</td>
<td>Bottle packaging dropped by sponsor</td>
</tr>
<tr>
<td>(b) (4)</td>
<td>III</td>
<td>(b) (4)</td>
<td></td>
<td>7</td>
<td>N/A</td>
<td>-</td>
<td>Bottle packaging dropped by sponsor</td>
</tr>
<tr>
<td>(b) (4)</td>
<td>III</td>
<td>(b) (4)</td>
<td></td>
<td>7</td>
<td>N/A</td>
<td>-</td>
<td>Bottle packaging dropped by sponsor</td>
</tr>
</tbody>
</table>

1 Action codes for DMF Table:
1 – DMF Reviewed.
Other codes indicate why the DMF was not reviewed, as follows:
2 – Type 1 DMF
3 – Reviewed previously and no revision since last review
4 – Sufficient information in application
5 – Authority to reference not granted
6 – DMF not available
7 – Other (explain under "Comments")

2 Adequate, Inadequate, or N/A (There is enough data in the application, therefore the DMF did not need to be reviewed)
B. Other Documents:

<table>
<thead>
<tr>
<th>DOCUMENT</th>
<th>APPLICATION NUMBER</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>IND</td>
<td>70,139</td>
<td>FTY720D Capsules for the Treatment of Multiple Sclerosis</td>
</tr>
<tr>
<td>IND</td>
<td>57,293</td>
<td>FTY720A for the Treatment of Prophylaxis of Organ Rejection</td>
</tr>
<tr>
<td>IND</td>
<td>70,407</td>
<td>FTY720 for the Treatment of Hepatitis C</td>
</tr>
</tbody>
</table>

18. STATUS:

<table>
<thead>
<tr>
<th>CONSULTS/ CMC RELATED REVIEWS</th>
<th>RECOMMENDATION</th>
<th>DATE</th>
<th>REVIEWER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biometrics</td>
<td>Pending</td>
<td></td>
<td>X. Yan</td>
</tr>
<tr>
<td>EES</td>
<td>Acceptable</td>
<td>03-FEB-2010</td>
<td>M. Stock</td>
</tr>
<tr>
<td>Pharm/Tox</td>
<td>Pending</td>
<td></td>
<td>R. Siarey</td>
</tr>
<tr>
<td>Biopharm</td>
<td>Pending</td>
<td></td>
<td>J. Lai</td>
</tr>
<tr>
<td>LNC</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methods Validation</td>
<td>Method validation by FDA laboratory not needed</td>
<td>20-JAN-2010</td>
<td>W. Wilson-Lee</td>
</tr>
<tr>
<td>DMEPA</td>
<td>Objection to proposed tradename, Gilenia®</td>
<td>05-MAY-2010</td>
<td>F. Duffy</td>
</tr>
<tr>
<td>EA</td>
<td>Categorical exclusion granted.</td>
<td>31-AUG-2009</td>
<td>W. Wilson-Lee</td>
</tr>
<tr>
<td>Microbiology</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>
List of Tables

Table 1 – Fingolimod Dissociation Constants in Mixtures ...............................................................................................................................12
Table 2 – Fingolimod Hydrochloride Distribution Coefficients .....................................................................................................................12
Table 3 – Solubilities of Fingolimod Hydrochloride at 25°C .............................................................................................................................12
Table 4 – Solubilities of Fingolimod Hydrochloride at 37°C .............................................................................................................................12
Table 5 – Known Polymorphs of Fingolimod Hydrochloride ..........................................................................................................................13
Table 6 – Comparison of the Physicochemical Properties of Fingolimod Hydrochloride .............................................................................13
Table 7 – Comparison of the Stability of Fingolimod Hydrochloride Near the Transition Temperature .........................................................14
Table 8 – Fingolimod Hydrochloride Manufactures ..................................................................................................................................14
Table 9 – Nomenclature Index for Fingolimod Hydrochloride Synthesis .....................................................................................................14
Table 10 – Fingolimod Hydrochloride Critical Process Parameters .........................................................................................................17
Table 11 – Fingolimod Hydrochloride Starting Materials ............................................................................................................................18
Table 12 – Fingolimod Hydrochloride Critical Quality Attributes ...............................................................................................................26
Table 13 – Fingolimod Hydrochloride In-Process Tests .................................................................................................................................26
Table 14 – Fingolimod Hydrochloride Specification and Test Methods ........................................................................................................27
Table 15 – Fingolimod Hydrochloride Manufacturing Development .........................................................................................................28
Table 16 – Summary of Fingolimod Hydrochloride Manufacturing Development ............................................................................................28
Table 17 – UV Absorption of Fingolimod Hydrochloride in Various Media ....................................................................................................29
Table 18 – Fingolimod Hydrochloride Particle Size Distribution History .....................................................................................................29
Table 19 – Fingolimod Hydrochloride Organic Impurities .............................................................................................................................30
Table 20 – Potential Residual Solvents in Fingolimod Hydrochloride ............................................................................................................31
Table 21 – Residual Heavy Metals in Fingolimod Hydrochloride .........................................................................................................................32
Table 22 – Assessment of Potentially Genotoxic Impurities in Fingolimod Hydrochloride ........................................................................32
Table 23 – Summary of Impurity Profile of Fingolimod Hydrochloride ........................................................................................................33
Table 24 – Residual Contents of DMF in Fingolimod Hydrochloride .................................................................................................................33
Table 25 – Residual Charge of Residual Contents in Fingolimod Hydrochloride .............................................................................................33
Table 26 – Proposed Fingolimod Hydrochloride Regulatory Specification ..................................................................................................34
Table 27 – Assessment of Qualification of Fingolimod Hydrochloride Impurities ........................................................................................35
Table 28 – Residual Solvent Contents in Final Isolated Intermediate .............................................................................................................35
Table 29 – Synthesis-related Impurities of Fingolimod Hydrochloride ........................................................................................................36
Table 30 – Synthesis-related Impurities of Fingolimod Hydrochloride ........................................................................................................36
Table 31 – Residual Contents of DMF and in Fingolimod Hydrochloride .........................................................................................................37
Table 32 – Particle Size Regulatory Method Conditions .................................................................................................................................37
Table 33 – Assay and Impurities Regulatory Method Chromatographic Conditions ..........................................................................................38
Table 34 – Residual Solvents Regulatory Method Chromatographic Conditions ..................................................................................................38
Table 35 – Summary of Fingolimod Hydrochloride Regulatory Analytical Method Validation Activities ............................................................40
Table 36 – Significant Peak Positions of Different Polymorphs of Fingolimod Hydrochloride by X-Ray Diffraction ........................................40
Table 37 – Summary of LOQ Values for GC Regulatory Method ..................................................................................................................41
Table 67 - Summary of LOD Values for GC Regulatory Method
Table 68 - Summary of LOD Values for ICP Regulatory Method
Table 69 - Summary of Fingolimod Hydrochloride Registration Batches
Table 70 - Batch Analysis Results for Fingolimod Hydrochloride Registration Batches
Table 71 - Summary of Storage Conditions for Fingolimod Hydrochloride Reference Standard
Table 72 - Batch Analysis Results for Current Fingolimod Hydrochloride Reference Standard (Batch 0324027.REF)
Table 73 - Summary of Fingolimod Hydrochloride Stability Batches
Table 74 - Fingolimod Hydrochloride Post-Approval Stability Protocol: Tests at Long-Term Conditions
Table 75 - Fingolimod Hydrochloride Post-Approval Stability Protocol: Stability Specification
Table 76 - Summary of Fingolimod Hydrochloride Long-Term Stability (Batches 0324019, 0324020, and 0324021): Month 0 - 12
Table 77 - Summary of Fingolimod Hydrochloride Long-Term Stability (Batches 0324019, 0324020, and 0324021): Month 18 - 60
Table 78 - Summary of Fingolimod Hydrochloride Intermediate Stability (Batches 0324019, 0324020, and 0324021)
Table 79 - Summary of Fingolimod Hydrochloride Accelerated Stability (Batches 0324019, 0324020, and 0324021)
Table 80 - Summary of Fingolimod Hydrochloride Refrigerated Stability (Batches 0324019, 0324020, and 0324021)
Table 81 - Summary of Fingolimod Hydrochloride Frozen Stability (Batches 0324019, 0324020, and 0324021)
Table 82 - Fingolimod Hydrochloride Photostability Data
Table 83 - Fingolimod Hydrochloride Stability: Effect of Increasing Temperature
Table 84 - Fingolimod Capsules Batch Formula: Effect of Purging at 40°C
Table 85 - Fingolimod Hydrochloride Stability: Effect of Purging at 80°C
Table 86 - Summary of Fingolimod Hydrochloride Forged Degradation Results
Table 87 - Effect of Storage on Fingolimod Hydrochloride Particle Size Distribution
Table 88 - Fingolimod Capsules Composition
Table 89 - Hard Gelatin Capsule Composition
Table 90 - Printing Ink Compositions
Table 91 - Summary of Fingolimod Hydrochloride Particle Size on 0.25 mg Capsule Uniformity
Table 92 - Development Batch Formulations Comparing Lubricant Type
Table 93 - Effect of Lubricant Type on Content Uniformity and Dissolution
Table 94 - Summary of Fingolimod Hydrochloride Development Batches
Table 95 - Development Batch Formulations With Different Diluents and Lubricants
Table 96 - Composition of Fingolimod Hydrochloride Injection Formulation
Table 97 - Development Capsule Formulations
Table 98 - Development Capsule Formulations
Table 99 - Dissolution in 0.1 N HCl
Table 100 - Comparison of Stability Dissolution Results With and Without Surfactant
Table 101 - Summary of Dissolution Results at Intermediate Conditions in Blisters
Table 102 - Effect of Lubricant Type on Dissolution Type
Table 103 - Summary of Dissolution Results from Different Packaging Configurations
Table 104 - Summary of Content Uniformity DOE (1.25 mg capsules)
Table 105 - Fingolimod Capsules Manufacturers
Table 106 - Fingolimod Capsules Batch Formula
Table 107 - SUPAC Equipment Class and Subclass for Fingolimod Capsules
Table 108 - Fingolimod Capsules In-Process Controls
Table 109 - Assessment of Fingolimod Capsules Critical Process Parameters
Table 110 - Fingolimod Capsules Content Uniformity Across an Encapsulation Run
Table 111 - Summary of Blend Uniformity for Fingolimod Capsules Final Blend
Table 112 - Summary of Fingolimod Capsules Excipient Specifications
Table 113 - Proposed Fingolimod Capsules Regulatory Specifications
Table 114 - Proposed Fingolimod Capsules Regulatory Apparatus Conditions
Table 115 - Fingolimod Capsules Regulatory Dissolution Apparatus Conditions
Table 116 - Fingolimod Capsules Regulatory Dissolution Chromatographic Conditions
Table 117 - Fingolimod Capsules Regulatory Uniformity of Dosage Units Chromatographic Conditions
Table 118 - Fingolimod Capsules Regulatory Identification, Assay, and Degradation Products Chromatographic Conditions
Table 119 - Fingolimod Capsules Regulatory Dissolution Automated Sampler Validation Criteria
Table 120 - Fingolimod Capsules Regulatory Dissolution Automated Sampler Validation Criteria
Table 121 - Summary of Fingolimod Capsules Regulatory Assay Method Validation
Table 122 - Summary of Fingolimod Capsules Regulatory Related Substances Method Validation
Table 123 - Summary of Fingolimod Capsules Regulatory Identification by TLC Method Validation
Table 124 - Summary of Fingolimod Capsules Regulatory Dissolution Method Validation
Table 125 - Summary of Fingolimod Capsules Regulatory Identification Method Validation
Table 126 - Summary of Fingolimod Capsules Regulatory Content Uniformity Method Validation
Table 127 - Summary of Fingolimod Capsules Regulatory Dissolution Method Validation: 0.5 mg Capsule
Table 128 - Fingolimod Capsules Regulatory Assay and Related Substances Sample Stability: 0.5 mg
Table 129 - Summary of Fingolimod Capsules Stability Batches
Table 130 - Summary of Fingolimod Capsules Stability Batch Analysis Results
Table 131 - Summary of Individual 30 minute Dissolution Results: Blisters at Long-term Conditions
Table 132 - Summary of Fingolimod Capsules Individual Dissolution Results: Blisters at Long-term Conditions for 24 Months
Table 133 - Fingolimod Capsules Specified Impurities
Table 134 - Summary of Peak Identifications for Potential Fingolimod Capsules Impurities and Degradants
Table 135 - Fingolimod Capsules To-Re-Marketed Packaging Configurations
Table 136 - Blister Specification
Table 137 - Summary of Fingolimod Capsules Registration and Stability Batches
Table 138 - Summary of Fingolimod Capsules Stability Batch Packaging Configuration
Table 139 - Summary of Proposed Fingolimod Capsules Expiry and Storage Conditions
Table 140 - Fingolimod Capsules Registration Batch Stability Protocol
Table 141 - Fingolimod Capsules Post-Approval Stability Protocol
Table 142 - Fingolimod Capsule Annual Stability Protocol
Table 143 - Fingolimod Capsules Stability Testing Program to Support Post-Approval Changes
Table 144 - Summary of Fingolimod Capsules Long-term Stability Results
Table 145 - Summary of Fingolimod Capsules Intermediate Stability Results
Table 146 - Summary of Fingolimod Capsules Accelerated Stability Results
Table 147 - Summary of Fingolimod Capsules Stability Results (Batch H375BD in Blisters): Effect of Temperature Extremes
Table 148 - Summary of Fingolimod Capsules Photosability Results (Batch H375BD)
Table 149 - Summary of Fingolimod Capsules Microbiological Purity Results
Table 150 - Fingolimod Capsules Stability Data Poolability Analysis
Table 151 - Analysis of Variance of Final Model
Table 152 - Calculated Fingolimod Capsules Shelf-Life
Table 153 - Summary of Fingolimod Capsules Executed Batch Record
Table 154 - Summary of Fingolimod Capsules Methods Validation Package Samples
Table 155 - Production Estimates for Fingolimod Capsules
Table 156 - Fingolimod Hydrochloride EES Request Summary
Table 157 - Fingolimod Capsules EES Request Summary
Table 158 - NDA 22-527 EES Detail Report

List of Figures

Figure 1 - Fingolimod Hydrochloride
Figure 2 - Fingolimod Hydrochloride
Figure 3 - Fingolimod Hydrochloride DSC and TGA Analyses
Figure 4 - Fingolimod Hydrochloride Synthetic Scheme
Figure 5 - Contribution of Starting Materials to Final Fingolimod Hydrochloride Structure
Figure 6 - Fingolimod Hydrochloride Post-Approval Stability Protocol: Testing Schedule for Registration Batches
Figure 7 - Effect of Surfactant on Dissolution in 0.1 N HCl
Figure 8 - Drug Product Manufacturing Process: Two Screening Steps vs. One Screening Step
Figure 9 - Fingolimod Capsules Manufacturing Process
Figure 10 - Stability Analysis of Blisters at Long-term Conditions
Figure 11 - Fingolimod Capsules Assay Results: Blisters at Long-term Conditions
Figure 12 - Fingolimod Capsules Dissolution Results: Blisters at Long-Term Conditions
Figure 13 - Proposed Fingolimod Capsules Physician Sample Packaging
Figure 14 - Proposed Fingolimod Capsules Trade Blister Packaging - 7-count
Figure 15 - Proposed Fingolimod Capsules Trade Blister Packaging - 28-count
Figure 16 - Revised Fingolimod Capsules Trade Blister Packaging - 7-count
Figure 17 - Revised Fingolimod Capsules Trade Blister Packaging - 28-count
Figure 18 - Revised Fingolimod Capsules Physician Sample Packaging
The Executive Summary

I. Recommendations

A. Recommendation and Conclusion on Approvability

From a CMC perspective, we recommend a complete response for fingolimod capsules 0.5 mg, pending a response to our information request and labeling.

B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable

We have no CMC Phase 4 commitments at this time.

II. Summary of Chemistry Assessments

A. Description of the Drug Product(s) and Drug Substance(s)

Fingolimod hydrochloride, a novel synthetic sphingosine analogue, is an S1P-receptor modulator that reversibly traps a proportion of lymphocytes in the lymph nodes, thereby reducing their recirculation in the bloodstream and the central nervous system. The drug substance is a white to practically white powder. During development of the drug substance, the base and salts of fingolimod were manufactured and tested for stability, solubility and polymorphic properties. Based on this testing, the hydrochloride salt was chosen for further development. It exhibited the best solubility characteristics in both water and 0.1 N HCl and the best stability characteristics with a standard excipient mixture.

Fingolimod hydrochloride is the desired form used throughout the toxicity and clinical program.

The sponsor manufactures fingolimod in

The structural elucidation data support the proposed structure of fingolimod hydrochloride. The identity and quality of the drug substance is assured through appropriate in-process controls and adequate final drug substance specification. The drug substance specification includes tests and acceptance criteria for description, particle size distribution, color and clarity of solution, identity (IR and XRPD), chromatographic purity (HPLC), residual solvents, heavy metals, water, assay...
(HPLC), chloride assay, and microbiological purity. All analytical methods are validated for their intended use. Novartis proposes a rest period for the drug substance.

Fingolimod 0.5 mg hard gelatin capsules are an immediate release dosage form for oral administration. The 0.5 mg strength drug product is a size 3 capsule with a white, opaque body and a bright yellow, opaque cap that contains white to practically white powder. The capsule has a “FTY 0.5 mg” radial imprint on the cap and two radial bands imprinted on the body with yellow ink. All of the formulation excipients as well as the capsule and ink components comply with compendial or regulatory standards. The drug product does not contain any novel excipients.

The manufacturing process is straightforward and consists of encapsulation, and packaging. The drug product quality is controlled through appropriate in-process controls and final product specification. The drug product specification includes tests and acceptance criteria for appearance, identification (TLC, HPLC), single-point dissolution, degradation products (HPLC), assay (HPLC), uniformity of dosage forms by content uniformity, and microbial purity. All analytical procedures are appropriately validated for their intended use. The commercial packaging is blister packs. Novartis proposes a 24 month expiry for this product when stored in the commercial packaging at 25ºC (77ºF); excursions permitted to 15-30ºC (59-86ºF), protected from moisture.

B. Description of How the Drug Product is Intended to be Used

Fingolimod capsules are indicated as a disease modifying therapy for the treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability. The daily recommended dose of fingolimod capsules is 0.5 mg. Fingolimod 0.5 mg capsules are for oral administration once daily, with or without food. Fingolimod capsules are supplied in blister packs as a carton of 28 capsules or a carton of 7 capsules (one blister strip of 7 capsules).

C. Basis for Approvability or Not-Approval Recommendation

From a CMC perspective, we recommend a complete response for fingolimod capsules 0.5 mg, pending response to our information request and labeling. We sent 10 additional comments to the sponsor on 07-MAY-2010 regarding recommended changes to the drug substance and drug product controls (see Section III of this review). The assessment of the qualification of one drug product degradant by the pharm/tox review team is also pending.

III. Administrative

A. Reviewer’s Signature

Wendy I. Wilson-Lee

B. Endorsement Block

WWilson-Lee: 30-APR-2010
MHeimann: 07-MAY-2010
RSood: 11-MAY-2010

C. CC Block

DHenry
HToumet
<table>
<thead>
<tr>
<th>Application Type/Number</th>
<th>Submission Type/Number</th>
<th>Submitter Name</th>
<th>Product Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA-22527</td>
<td>ORIG-1</td>
<td>NOVARTIS PHARMACEUTICALS CORP</td>
<td>FINGOLIMOD HCL ORAL CAPSULES</td>
</tr>
</tbody>
</table>

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

WENDY I WILSON
05/12/2010

RAMESH K SOOD
05/12/2010